Last reviewed 2026-04-23 · How we verify

JNT-517 Tablet

JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.

JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Obesity or overweight with weight-related comorbidities.

At a glance

Mechanism of action

5-HT2C receptors are located in the hypothalamus and play a key role in appetite regulation. By selectively activating these receptors, JNT-517 enhances pro-opiomelanocortin (POMC) neuron signaling, which suppresses hunger signals and increases energy expenditure. This mechanism leads to reduced caloric intake and body weight reduction.

Approved indications

• Obesity or overweight with weight-related comorbidities

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Dizziness

Key clinical trials

• A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU) (PHASE3)
• A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (PHASE1)
• A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria (PHASE2)
• First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria (PHASE1, PHASE2)
• A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.